| Sign In to gain access to subscriptions and/or personal tools. |
Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-upDepartment of Internal Medicine, Haematology and Oncology, Albert-Ludwigs University, Freiburg, Germany
Department of Internal Medicine, Haematology and Oncology, Albert-Ludwigs University, Freiburg, Germany
Department of Internal Medicine, Haematology and Oncology, Albert-Ludwigs University, Freiburg, Germany
Department of Internal Medicine, Haematology and Oncology, Albert-Ludwigs University, Freiburg, Germany, carsten.gruellich{at}uniklinik-freiburg.de An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell dysfunction may be involved in its pathogenesis. Antiphospholipid antibody syndrome with autoimmune cytopenias shows a poor response rate to conventional treatment with anticoagulants, glucocorticosteroids, immunosuppressive agents, intravenous immunoglobulin or plasmapheresis. We report a case of life-threatening antiphospholipid antibody syndrome with Evans syndrome receiving successful multimodal treatment including anti-CD20 monoclonal antibody rituximab with long-term follow-up.
Key Words: antiphospholipid antibody syndrome hemolytic anemia rituximab thrombocytopenia
Lupus, Vol. 17, No. 8,
757-760 (2008) |
||||